Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 3/20 | 0.54 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.52 |
| ▸ | KDR | P35968 | 8/20 | 0.51 |
| ▸ | RAF1 | P04049 | 1/20 | 0.51 |
| ▸ | BRAF | P15056 | 4/20 | 0.49 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.48 |
| ▸ | CA1 | P00915 | 1/20 | 0.48 |
| ▸ | CA2 | P00918 | 1/20 | 0.48 |
| ▸ | CA7 | P43166 | 1/20 | 0.48 |
| ▸ | CA9 | Q16790 | 1/20 | 0.48 |
| ▸ | KIT | P10721 | 1/20 | 0.47 |
| ▸ | FLT3 | P36888 | 1/20 | 0.47 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.47 |
| ▸ | TEK | Q02763 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3880514 | 0.90 | RIPK1 (0.52) | TRPV1RIPK1KDRBRAFGRM4 | |
| SCHEMBL3878463 | 0.89 | GRM4 (0.45) | TRPV1RIPK1KDRBRAFGRM4 | |
| SCHEMBL3877565 | 0.87 | RIPK1 (0.54) | TRPV1RIPK1KDRRAF1BRAF | |
| SCHEMBL1877708 | 0.86 | RIPK1 (0.58) | TRPV1RIPK1KDRRAF1BRAF | |
| SCHEMBL3878842 | 0.86 | MTOR (0.47) | TRPV1KDRPDGFRB | |
| SCHEMBL3885329 | 0.85 | KDR (0.59) | RIPK1KDRKITFLT3PDGFRB | |
| SCHEMBL3881695 | 0.85 | KDR (0.48) | TRPV1RIPK1KDRKITFLT3 | |
| SCHEMBL3879079 | 0.85 | KDR (0.55) | TRPV1RIPK1KDRRAF1BRAF | |
| SCHEMBL3881680 | 0.83 | RIPK1 (0.54) | TRPV1RIPK1KDRCA1CA2 | |
| SCHEMBL3885659 | 0.82 | HPSE (0.50) | KDRGRM4KITFLT3TEK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070259910-A1 | Substituted Indoles, Compositions Containing Them, Method for the Production Thereof and Their Use | AVENTIS PHARMA S.A. (FR) | 2007-11-08 | — | — | US | claimed |
| EP-1841762-A1 | SUBSTITUTED INDOLES, COMPOSITIONS CONTAINING THEM, METHOD FOR THE PRODUCTION THEREOF AND THEIR USE | Aventis Pharma S.A. (FR) | 2007-10-10 | — | — | EP | claimed |
| WO-2006061493-A1 | SUBSTITUTED INDOLES, COMPOSITIONS CONTAINING THEM, METHOD FOR THE PRODUCTION THEREOF AND THEIR USE | AVENTIS PHARMA S.A. (FR) | 2006-06-15 | — | — | WO | claimed |
| US-7566736-B2 | Substituted indoles, compositions containing them, method for the production thereof and their use | AVENTIS PHARMA S.A. (FR) | 2009-07-28 | — | — | US | disclosed |
| US-7566736-B2 | Substituted indoles, compositions containing them, method for the production thereof and their use | AVENTIS PHARMA S.A. (FR) | 2009-07-28 | — | — | US | disclosed |
| US-7566736-B2 | Substituted indoles, compositions containing them, method for the production thereof and their use | AVENTIS PHARMA S.A. (FR) | 2009-07-28 | — | — | US | disclosed |
| US-20070259910-A1 | Substituted Indoles, Compositions Containing Them, Method for the Production Thereof and Their Use | AVENTIS PHARMA S.A. (FR) | 2007-11-08 | — | — | US | disclosed |
| US-20070259910-A1 | Substituted Indoles, Compositions Containing Them, Method for the Production Thereof and Their Use | AVENTIS PHARMA S.A. (FR) | 2007-11-08 | — | — | US | disclosed |
| US-20070259910-A1 | Substituted Indoles, Compositions Containing Them, Method for the Production Thereof and Their Use | AVENTIS PHARMA S.A. (FR) | 2007-11-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070259910-A1 | Substituted Indoles, Compositions Containing Them, Method for the Production Thereof and Their Use | IDO1, RB1, IDO2 | TRPV1 4169/4885RIPK1 2658/4885KDR 1690/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.